Digital cognitive behavioral therapy can improve anxiety and asthma control

A new study shows that internet-delivered cognitive behavioral therapy (ICBT) can effectively reduce asthma-related anxiety ...

Immune system plays a major role in brain damage after repeated concussions, study suggests

From football fields to military training grounds, head injuries are leaving lasting marks on the brain in ways we're only ...
BioSpace

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of ...
Pharmabiz

Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy

Omeros Corporation, an innovative biotechnology company, announced that the US Food and Drug Administration (FDA) has approved Yartemlea (narsoplimab-wuug) for the treatment of hematopoietic stem cell ...
Nasdaq

Omeros Wins FDA Approval For YARTEMLEA In Transplant-Associated Thrombotic Microangiopathy

(RTTNews) - Omeros Corporation (OMER) today announced that the FDA has approved YARTEMLEA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and ...
MarketWatch

Omeros Gets FDA Approval of Yartemlea

Omeros has won U.S. Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants. Omeros on Wednesday said the approval covers Yartemlea ...
Times Argus

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of hematopoietic stem cell ...
grafa

Omeros surges as FDA clears Yartemlea as first-ever stem cell complication therapy

Omeros Corporation (NASDAQ:OMER) said the U.S. Food and Drug Administration approved YARTEMLEA (narsoplimab-wuug) to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy, ...
Yahoo Finance

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

First and only approved option: YARTEMLEA ® is the only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) and is indicated for adults and ...